Showing 1701-1710 of 2050 results for "".
- Oculis Announces Publication and Presentation of Phase 2 Data Showing Topical OCS-01 Improves Macular Thickness and Visual Acuity in Patients with DMEhttps://modernod.com/news/oculis-announces-publication-and-presentation-of-phase-2-data-showing-topical-ocs-01-improves-macular-thickness-and-visual-acuity-in-patients-with-dme/2481066/Oculis SA announced that the phase 2 DX-211, a randomized, double blinded, multicenter and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with diabetic macular edema (DME) (NCT05343156) has been published in the journal Acta Ophthalmolog
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C
- Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-initial-clinical-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481028/Viridian Therapeutics announced positive initial clinical data from the 10mg/kg cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). The double-blind, placebo-controlled phase 1/2 trial is evaluating
- CooperVision MiSight 1 Day Officially Launches in Chinahttps://modernod.com/news/coopervision-misight-1-day-officially-launches-in-china/2481026/CooperVision and EssilorLuxottica have officially launched MiSight 1 day contact lenses in China, marking its availability in the world’s largest country for myopia management. It is the first product of any type that has an indication from the Chinese National Medical Products Adminis
- Study: Neurolenses Have Significant Impact on Reading Speedhttps://modernod.com/news/neurolenses-have-significant-impact-on-reading-speed/2481017/As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and producti
- Lenstec Receives FDA Approval for the SBL-3 Multifocal IOLhttps://modernod.com/news/lenstec-receives-fda-approval-for-sbl-3-multifocal-iol/2481002/Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next-generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensit
- Waldo Launches Hydra Boost Plus Lenses in the United Stateshttps://modernod.com/news/waldo-launches-hydra-boost-plus-lenses-in-the-united-states/2480962/Waldo announced the launch of Hydra Boost Plus contact lenses, now available at
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoints-in-dry-eye-disease-chamber-crossover-clinical-trial/2480957/Aldeyra Therapeutics announced the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was st
- Oyster Point Pharma Announces Restructuring Plan to Reduce Costshttps://modernod.com/news/oyster-point-pharma-announces-operating-expense-streamlining-plan/2480938/Oyster Point Pharma announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 fie
- Kubota Vision Announces End-of-Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announced-end-of-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2480932/Kubota Vision announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (emixustat) in patients with macular atrophy secondary to Stargardt disease. The study was a multicenter, randomized, double-masked, and placebo-controlled phase 3 clini